Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annika Nelde

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
JCI Insight|April 24, 2019
Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccineElodie Belnoue, Jean-François Mayol, Susanna Carboni, et al.
Cellular and Molecular Life Sciences : CMLS|March 3, 2022
Upstream open reading frames regulate translation of cancer-associated transcripts and encode HLA-presented immunogenic tumor antigensAnnika Nelde, Lea Flötotto, Lara Jürgens, et al.
Oncoimmunology|April 11, 2018
HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapyAnnika Nelde, Daniel J Kowalewski, Linus Backert, et al.
Frontiers in Oncology|October 29, 2024
AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patientsSusanne Jung, Annika Nelde, Yacine Maringer, et al.
Journal for Immunotherapy of Cancer|October 9, 2025
Exceptional tumor-free survival of a patient with metastatic intrahepatic cholangiocarcinoma after surgery and personalized peptide vaccination: revisiting a striking caseAna Maia, Juliane Schuhmacher, Silvio Nadalin, et al.
Frontiers in Oncology|September 10, 2024
iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimensAlexander Englisch, Clara Hayn, Susanne Jung, et al.
European Journal of Immunology|August 23, 2021
SARS-CoV-2-reactive T-cell receptors isolated from convalescent COVID-19 patients confer potent T-cell effector functionFabian Brunk, Andreas Moritz, Annika Nelde, et al.
Iscience|November 28, 2022
Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunityAnnika Nelde, Jonas Rieth, Malte Roerden, et al.
Frontiers in Immunology|July 26, 2021
Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic LeukemiaAnnika Nelde, Yacine Maringer, Tatjana Bilich, et al.
Blood|July 4, 2015
The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapySimon Walz, Juliane S Stickel, Daniel Johannes Kowalewski, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
JCI Insight|April 24, 2019
Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccineElodie Belnoue, Jean-François Mayol, Susanna Carboni, et al.
Cellular and Molecular Life Sciences : CMLS|March 3, 2022
Upstream open reading frames regulate translation of cancer-associated transcripts and encode HLA-presented immunogenic tumor antigensAnnika Nelde, Lea Flötotto, Lara Jürgens, et al.
Oncoimmunology|April 11, 2018
HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapyAnnika Nelde, Daniel J Kowalewski, Linus Backert, et al.
Frontiers in Oncology|October 29, 2024
AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patientsSusanne Jung, Annika Nelde, Yacine Maringer, et al.
Journal for Immunotherapy of Cancer|October 9, 2025
Exceptional tumor-free survival of a patient with metastatic intrahepatic cholangiocarcinoma after surgery and personalized peptide vaccination: revisiting a striking caseAna Maia, Juliane Schuhmacher, Silvio Nadalin, et al.
Frontiers in Oncology|September 10, 2024
iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimensAlexander Englisch, Clara Hayn, Susanne Jung, et al.
European Journal of Immunology|August 23, 2021
SARS-CoV-2-reactive T-cell receptors isolated from convalescent COVID-19 patients confer potent T-cell effector functionFabian Brunk, Andreas Moritz, Annika Nelde, et al.
Iscience|November 28, 2022
Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunityAnnika Nelde, Jonas Rieth, Malte Roerden, et al.
Frontiers in Immunology|July 26, 2021
Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic LeukemiaAnnika Nelde, Yacine Maringer, Tatjana Bilich, et al.
Blood|July 4, 2015
The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapySimon Walz, Juliane S Stickel, Daniel Johannes Kowalewski, et al.
Pageof 6